Skip to main content
. 2021 May 19;8(1):e000638. doi: 10.1136/bmjgast-2021-000638

Table 2.

Low, intermediate, high risk FLI

Low risk Intermediate risk High risk (FLI ≥60) (N=553) P value*
(FLI ≤30) (FLI 30–60)
(N=393) (N=299)
Age 57±16 60±14 60±12 <0.01
Gender <0.01
 Male 141 (35.9%) 159 (53.4%) 313 (56.6%)
 Female 252 (64.1%) 140 (46.8%) 240 (43.4%)
Obesity <0.01
 BMI <30 387 (98.5%) 256 (85.6%) 182 (32.9%)
 BMI ≥30 6 (1.5%) 43 (14.4%) 371 (67.1%)
WC (cm) 83.1±8.9 95.6±6.8 109.8±12.3 <0.01
Alcohol <0.01
 Non-drinker 65 (16.9%) 56 (19.2%) 143 (26.2%)
 Within limits 287 (74.7%) 211 (72.3%) 313 (57.3%)
 Above limits 32 (8.3%) 25 (8.6%) 90 (16.5%)
Hypertension 81 (20.6%) 93 (31.1%) 247 (44.7%) <0.01
Type 2 diabetes 19 (4.8%) 27 (9.1%) 112 (20.3%) <0.01
Prior diagnosis of fatty liver disease (NAFLD, fatty liver disease on imaging, alcohol-related fatty liver disease) 3 (0.8%) 4 (1.34%) 30 (5.43%) <0.01
Statin 84 (21.4%) 96 (32.1%) 214 (38.7%) <0.01
ALT 21.8±14.9 24.0±11.1 32.8±22.2 <0.01
Elevated ALT >1× ULN 18 (4.7%) 16 (5.4%) 108 (20.0%) <0.01
AST 25.4±11.6 25.8±7.9 30.3±17.3 0.07
Elevated AST >1× ULN 18 (4.9%) 10 (3.6%) 72 (14.0%) <0.01
GGT 21.8±14.0 31.5±21.5 75.9±177.1 <0.01
IgA 2.3±1.0 2.5±1.2 2.7±1.3 <0.01
Triglyceride 0.8±0.3 1.1±0.4 1.9±1.8 <0.01
HDL-cholesterol 1.7±0.4 1.5±0.4 1.3±0.4 <0.01
HbA1c 37.0±7.0 38.8±10.3 42.6±12.1 <0.01
Fasting glucose 4.8±1.1 5.2±2.1 5.9±2.0 <0.01
Age-adjusted FIB-4 risk 0.64
 Low 272 (74.9%) 194 (71.6%) 361 (70.8%)
 Intermediate 77 (21.2%) 65 (24.0%) 121 (23.7%)
 High 14 (3.9%) 12 (4.4%) 28 (5.5%)
Elevated QRISK 178 (46.8%) 184 (62.4%) 398 (72.6%) <0.01

*From Χ2 test/one-way ANOVA across the three groups.

ALT, alanine transferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; BMI, body mass index; FIB-4, Fibrosis-4; FLI, Fatty Liver Index; GGT, gamma glutamyltransferase; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; ULN, upper limit of normal; WC, waist circumference.